Jens Rasenack
Overview
Explore the profile of Jens Rasenack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fischer J, Weber A, Bohm S, Dickhofer S, El Maadidi S, Deichsel D, et al.
Gut
. 2016 May;
66(10):1829-1837.
PMID: 27196570
Objective: As pathogen sensors, Toll-like receptors (TLR) play a role in the first defence line during HCV infection. However, the impact of the DNA sensor TLR9 on the natural course...
2.
Pawlotsky J, Flisiak R, Sarin S, Rasenack J, Piratvisuth T, Chuang W, et al.
Hepatology
. 2015 Jun;
62(4):1013-23.
PMID: 26118427
Unlabelled: Alisporivir is a cyclophilin inhibitor with pan-genotypic anti-hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL-1 study assessed alisporivir as interferon (IFN)-free therapy in...
3.
Gane E, Deray G, Liaw Y, Lim S, Lai C, Rasenack J, et al.
Gastroenterology
. 2013 Sep;
146(1):138-146.e5.
PMID: 24067879
Background & Aims: There is a close relationship between chronic hepatitis B virus infection and chronic renal disease. We analyzed changes in renal function using different markers of glomerular filtration...
4.
Knop V, Teuber G, Klinker H, Moller B, Rasenack J, Hinrichsen H, et al.
Ann Hepatol
. 2013 Feb;
12(2):190-8.
PMID: 23396729
Introduction: Complete suppression of viral replication is crucial in chronic HCV treatment in order to prevent relapse and resistance development. We wanted to find out which factors influence the period...
5.
Wiegand J, Neumann K, Bohm S, Weich V, Teuber G, Klinker H, et al.
Clin Infect Dis
. 2011 Oct;
53(11):1111-4.
PMID: 22021919
This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia...
6.
Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, et al.
Hepatology
. 2009 Jul;
50(2):369-77.
PMID: 19575366
Unlabelled: Individualized treatment on the basis of early viral kinetics has been discussed to optimize antiviral therapy in chronic hepatitis C virus (HCV) infection. Individually tailored reduction in treatment duration...
7.
Zeuzem S, Gane E, Liaw Y, Lim S, DiBisceglie A, Buti M, et al.
J Hepatol
. 2009 Apr;
51(1):11-20.
PMID: 19345439
Background/aims: In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2 years. We analyzed all telbivudine recipients in this trial to determine...
8.
Lai C, Gane E, Liaw Y, Hsu C, Thongsawat S, Wang Y, et al.
N Engl J Med
. 2007 Dec;
357(25):2576-88.
PMID: 18094378
Background: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. Methods: In this double-blind, phase 3 trial, 1370 patients...
9.
Kamal S, Moustafa K, Chen J, Fehr J, Abdel Moneim A, Khalifa K, et al.
Hepatology
. 2006 Apr;
43(5):923-31.
PMID: 16628640
Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, and chronic evolution of the disease occurs in a majority of cases. To assess the efficacy and safety of...
10.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al.
Gastroenterology
. 2006 Apr;
130(4):1086-97.
PMID: 16618403
Background & Aims: The treatment of patients infected with hepatitis C virus (HCV) type 1 remains a challenge necessitating innovative strategies to improve treatment outcome. The extension of treatment duration...